News Releases

08 May '19
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--May 8, 2019-- Cortexyme, Inc. (Nasdaq: CRTX), a clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s and other degenerative diseases, today announced that it
04 Apr '19
SOUTH SAN FRANCISCO, Calif. —  Cortexyme, Inc., a privately held, clinical stage biopharmaceutical company pioneering a novel disease-modifying therapeutic approach to treat a key underlying cause of Alzheimer’s disease (AD) and other degenerative diseases, today announced the election of veteran
Displaying 11 - 18 of 18